Ion Beam Applications, SA

Declaration of Voting Results & Voting Rights Announcements • Jul 4, 2017

IBA – TRANSPARENCY NOTIFICATION

Louvain-la-Neuve, Belgium, July 03, 2017, 5.40 p.m. - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notifications received on 7 April 2017.

Reason for the notification	Upwards crossing of the 3% threshold further to
	the acquisition of shares –and thus voting rights
	held as loan collateral
Persons subject to the notification	IBA SA, issuer
requirement
Persons that dispose of voting rights	Norges Bank
Transaction date	29/06/2017
Threshold that is crossed (in %)	3% (statutory
	threshold)
	Upwards crossing
	further to the
	acquisition of voting
	rights
Denominator	29 852 549
Voting rights (number)	913 929
Voting rights (%)	3,06%
Chain of control	N/A

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and

Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

For further information, please contact:

IBA

Stephanie Bauwin Legal Counsel +32 10 203 924 Stephanie.bauwin@iba-group.com

Press release | 03/07/2017